Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response

BACKGROUND: Despite advances in the treatment of chronic urticaria, in a significant percentage of the patients symptoms are not fully controlled with conventional approaches. New strategies under development include blocking intracellular mediators of mast cell and basophil activation. OBJECTIVE: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Gimeno, Ramón, Ribas‐Llauradó, Clara, Pesque, David, Andrades, Evelyn, Cenni, Bruno, Ambros, Barbara, Pujol, Ramon, Giménez‐Arnau, Ana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985467/
https://www.ncbi.nlm.nih.gov/pubmed/36973953
http://dx.doi.org/10.1002/clt2.12227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985467/
https://www.ncbi.nlm.nih.gov/pubmed/36973953
http://dx.doi.org/10.1002/clt2.12227

Ejemplares similares